Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3040% below fair value
$1.73+0.03 (+1.76%)
Close on Nov 13, 2026Market cap $106.60MP/E –Yield –
Voyager Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Voyager Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -450.1%. For fiscal 2025 it was -326.6%, against -104.1% the year before. The highest annual figure on record is 48.8% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -326.6% | −222.4 |
| FY2024 | Dec 31, 2024 | -104.1% | −152.9 |
| FY2023 | Dec 31, 2023 | 48.8% | +173.1 |
| FY2022 | Dec 31, 2022 | -124.3% | +72.5 |
| FY2021 | Dec 31, 2021 | -196.8% | −212.8 |
| FY2020 | Dec 31, 2020 | 16.0% | +65.5 |
| FY2019 | Dec 31, 2019 | -49.5% | +1146.1 |
| FY2018 | Dec 31, 2018 | -1195.6% | −486.6 |
| FY2017 | Dec 31, 2017 | -709.1% | −418.6 |
| FY2016 | Dec 31, 2016 | -290.4% | −173.6 |
| FY2015 | Dec 31, 2015 | -116.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -658.2% | −429.3 |
| Q2 FY2026 | Jun 30, 2026 | -833.9% | −129.5 |
| Q1 FY2026 | Mar 31, 2026 | -1167.4% | −631.4 |
| Q4 FY2025 | Dec 31, 2025 | -195.2% | +414.9 |
| Q3 FY2025 | Sep 30, 2025 | -228.9% | −173.0 |
| Q2 FY2025 | Jun 30, 2025 | -704.3% | −653.5 |
| Q1 FY2025 | Mar 31, 2025 | -536.0% | −453.0 |
| Q4 FY2024 | Dec 31, 2024 | -610.1% | −670.1 |
| Q3 FY2024 | Sep 30, 2024 | -56.0% | +583.6 |
| Q2 FY2024 | Jun 30, 2024 | -50.8% | +473.1 |
| Q1 FY2024 | Mar 31, 2024 | -82.9% | −164.6 |
| Q4 FY2023 | Dec 31, 2023 | 60.0% | +24.9 |
| Q3 FY2023 | Sep 30, 2023 | -639.5% | +2080.6 |
| Q2 FY2023 | Jun 30, 2023 | -523.9% | +2720.8 |
| Q1 FY2023 | Mar 31, 2023 | 81.7% | +61.4 |
| Q3 FY2022 | Sep 30, 2022 | 35.2% | +1731.9 |
| Q2 FY2022 | Jun 30, 2022 | -2720.1% | −613.6 |
| Q1 FY2022 | Mar 31, 2022 | -3244.7% | −2851.1 |
| Q4 FY2021 | Dec 31, 2021 | 20.3% | +383.3 |
| Q3 FY2021 | Sep 30, 2021 | -1696.8% | −1768.5 |
| Q2 FY2021 | Jun 30, 2021 | -2106.5% | −2075.2 |
| Q1 FY2021 | Mar 31, 2021 | -393.6% | −258.4 |
| Q4 FY2020 | Dec 31, 2020 | -363.0% | −320.9 |
| Q3 FY2020 | Sep 30, 2020 | 71.7% | +158.9 |
| Q2 FY2020 | Jun 30, 2020 | -31.3% | −51.3 |
| Q1 FY2020 | Mar 31, 2020 | -135.2% | +428.4 |
| Q4 FY2019 | Dec 31, 2019 | -42.1% | +1111.3 |
| Q3 FY2019 | Sep 30, 2019 | -87.1% | +922.7 |
| Q2 FY2019 | Jun 30, 2019 | 19.9% | +1017.8 |
| Q1 FY2019 | Mar 31, 2019 | -563.7% | +1675.5 |
| Q4 FY2018 | Dec 31, 2018 | -1153.4% | −958.9 |
| Q3 FY2018 | Sep 30, 2018 | -1009.9% | +1024.5 |
| Q2 FY2018 | Jun 30, 2018 | -997.8% | +585.8 |
| Q1 FY2018 | Mar 31, 2018 | -2239.2% | −1042.3 |
| Q4 FY2017 | Dec 31, 2017 | -194.6% | +391.5 |
| Q3 FY2017 | Sep 30, 2017 | -2034.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -1583.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -1196.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -586.1% | – |
See a number that looks wrong?